ABBOTT PARK, Ill., Oct. 19, 2018/ PRNewswire/ Abbott announced today that the HeartMate 3? Left Ventricular Assist Device has received U.S. Food and Drug Administration approval as a destination therapy for people living with advanced heart failure. "Approximately a quarter of a million people are living with advanced heart failure, and many o
NORTH CHICAGO- AbbVie, a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic's oral integrin therapeutics for fibrosis-related...
In response to opinions expressed following the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee meeting on October 12, AcelRx Pharmaceuticals, Inc. stands by the safety, efficacy and medical need for its investigational therapy, DSUVIA?. Developed in collaboration with the Department of Defense, DSUVI
ADM Tronics Unlimited Inc. officials announced in a recent press release that the company has completed development and engineering to bring the Alvio Respiratory Therapy platform to production-ready status. Announced nearly a year ago, ADMT entered into an agreement with QoL Devices Inc., for development, regulatory activities, and manufacturing o
AELIX Therapeutics S.L., a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc., a research-based biopharmaceutical company that discovers, develops and commercializes innovative...
Amneal Pharmaceuticals, Inc., today announced that it has received FDA approval for a generic version of BiCNU for injection, 100 mg. About Amneal Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar
Amneal Pharmaceuticals, Inc., today announced that it has received FDA approval for a generic version of Isuprel TM Injection USP, 0.2 mg/mL and 1 mg/5 mL Single-Dose Vials. About Amneal Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is an integrated specialty pharmaceutical company focused on developing, manufacturing and distri
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer s disease, Rett syndrome and other central nervous system diseases, today announced that the Company has received confirmation from the U.S. Food and...
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer s disease, Rett syndrome and other central nervous system diseases, today announced that the Company has received confirmation from the U.S. Foo
Albany, NY 10/19/2018 Apocarotenal belongs to the group of plant substances called the carotenoid. The presence of Apocarotenal is usually seen in the citrus fruits and spinach. The main usage of Apocarotenal is in the coloring of food, beverages, cosmetics, and pharmaceutical industry.
Pune, India 10/19/2018 Auto-Injectors is defined as a medical device which is designed to deliver a single dose of a life-saving drug. Auto injectors are easy to use and are intended for self administration by patients or can be administered by untrained personnel. The Global Auto-Injectors Market is expected to reach USD 2.4 billion by th
AVITA Medical, a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL Autologous Cell Harvesting Device and has commenced commercial shipment of the product. Our immediate commercial focus is completing the recruitment and training of our U.S. field force.
Harrisburg, NC 10/19/2018 Marketinsightsreports provides "Global Bevacizumab Biosimilar Market Insights, Forecast To 2025" which includes the estimation of market size for value and volume. Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bevacizumab Biosimilar Market, to estimate the size of v
via NEWMEDIAWIRE BioCorRx Inc., a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company s R&D subsidiary, BioCorRx Pharmaceuticals, has acquired a portfolio of six Therakine Biodelivery GmbH patent families that broadly cover sustained release delivery platforms for t
CAMBRIDGE- Biogen announced it will present data from its Alzheimer's disease clinical development portfolio at the upcoming Clinical Trials on Alzheimer's Disease annual meeting in Barcelona, Spain. Aducanumab is Biogen's late-stage Alzheimer's disease investigational treatment, and is being co-developed with Eisai. Keynote: What Have We Learned..
BL-8040 in combination with KEYTRUDA demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer. Tel Aviv, Israel- BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced top-line results from the dual combination arm of the Phase 2 a...
The BSA Harrington Cancer Center has patients enrolled in a new study, aiming to prevent the reoccurrence of breast cancer. The BSA Harrington Cancer Center currently has seven different clinical trials focusing on breast cancer. Some patients at BSA Harrington Cancer Center have the option to join the Breast Cancer Weight Loss trial.
Albany, NY 10/19/2018 Calamus root is rich in vitamin C, hence taken as a dietary vitamin supplement on the regular basis to nourish the replicating cells. Since calamus root supplement is obtained from a natural source, consumers show more towards it. Due to the presence of anti-oxidant nutrients, calamus root is highly utilized in nutraceut
PETACH TIKVA- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, today announced that its CEO, Dr. Can-Fite's is currently enrolling patients for a Phase II NAFLD/NASH study in three Israeli sites, including Hadassah Medical Center, Jerusalem, and t
According to report by Grand View Research, Inc. The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022. The market to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, and availability of effective treatment methods, including target speci
At this year s American Society of Radiation Oncology annual meeting in San Antonio, Texas, October 21-24, 2018, Canon Medical Systems USA, Inc. will showcase its recently FDA- cleared Aquilion Precision TM, the world s first Ultra-High Resolution CT system. The Aquilion Precision sets a new bar for CT imaging, said Dominic Smith, senio
Los Angeles, CA 10/19/2018 This report studies the global market size of Cardiac Monitoring Products in key regions like North America, Europe, Asia Pacific, Central& South America and Middle East& Africa, focuses on the consumption of Cardiac Monitoring Products in these regions. This research report categorizes the global Cardiac Monitoring
ChemioCare USA Inc., a biotech company focused on transforming patient outcomes in cancer supportive care, today announces a successful Drug Enforcement Administration registration: ChemioCare s exclusive formulation development partner, Transdermal Research Pharm Laboratories LLC, has obtained a new registration with the DEA as a Manufacturer
Chemoinformatics Market is the use of computer and informational techniques applied to a range of problems in the field of chemistry. These techniques are used, in pharmaceutical companies in the process of drug discovery. These methods can also be...
Hutchison China MediTech Limited has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in combination with azacitidine, an approved nucleoside metabolic inhibitor, in elderly patients with acute myeloid leukemia in China. This study complements the ongoing Phase Ib dose expansion program of HMPL-523 in a broad range